GlobeNewswire Press Releases - EIN Presswire - Press Release Distribution Service

Published on June 7, 2026 - 23:00 GMT

NVIDIA and SK hynix Announce Multiyear Technology Partnership to Advance Memory for AI Factories

News Summary: NVIDIA and SK hynix announce multiyear technology partnership for next-generation memory aligned to NVIDIA’s AI infrastructure roadmap. The agreement supports supply for advanced memory, addressing the extended development cycles, advanced …

Distribution channels: Companies, Technology ...

Published on June 7, 2026 - 22:13 GMT

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Phreesia, Inc. Investors to Secure Counsel Before Important Deadline in ...

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Phreesia, Inc. (NYSE: PHR) between May 8, 2025 and March 30, 2026, inclusive (the “Class Period”), of the important …

Distribution channels:

Published on June 7, 2026 - 22:00 GMT

He Predicted Gold at $5,000. Now He Says This $2 Stock Could Be Even Bigger.

Washington, D.C., June 07, 2026 (GLOBE NEWSWIRE) -- When Jim Rickards told the world gold would hit $5,000 an ounce, most people laughed. Now gold has crossed that milestone and is heading higher. Nobody is laughing anymore. Today, Rickards is making …

Distribution channels: Consumer Goods ...

Published on June 7, 2026 - 21:55 GMT

MEDP DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before ...

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”), of …

Distribution channels:

Published on June 7, 2026 - 21:00 GMT

Diasome Presents Phase 2b Data Demonstrating HDV™-Insulin Lispro Maintains Glycemic Control While Reducing Hypoglycemia in Adults ...

HDV-Insulin Lispro (HDV-LIS) met A1C non-inferiority at Weeks 12 and 25, confirming comparable glycemic control to insulin lispro (LIS) with point-estimate differences below FDA-required 0.1% threshold HDV-LIS achieved statistically significant reductions …

Distribution channels: Healthcare & Pharmaceuticals Industry, IT Industry ...

Published on June 7, 2026 - 19:45 GMT

Canadian Employers Invited to Create 10,000 New Opportunities Through National Inclusive Hiring Campaign

BRAMPTON, Ontario, June 07, 2026 (GLOBE NEWSWIRE) -- Enabled Talent Canada today announced the launch of One Company. One Talent., a national campaign calling on Canadian employers to create at least one opportunity for a person with a disability or …

Distribution channels: Consumer Goods, Media, Advertising & PR ...

Published on June 7, 2026 - 19:40 GMT

GoHealth, Inc. to strengthen its position ahead of AEP 2026 through Restructuring Process supported by key stakeholders

Initiates voluntary prepackaged Chapter 11 process to implement Restructuring Transactions that have the support of 100% of its lenders, over 60% of the holders of GoHealth, Inc. Class A Common Stock, and over 99% of the holders of GoHealth Holdings, LLC …

Distribution channels:

Published on June 7, 2026 - 19:30 GMT

Photo Scanning Services 2026 - iMemories Launched Photo Scanning Services for Families Across the USA

New York City, NY, June 07, 2026 (GLOBE NEWSWIRE) -- Old photographs hold family records, milestone events, handwritten dates, wedding albums, childhood memories, and personal histories that become harder to protect with every passing year. Across American …

Distribution channels: IT Industry, Media, Advertising & PR ...

Published on June 7, 2026 - 18:30 GMT

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% ...

Company announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved …

Distribution channels:

Published on June 7, 2026 - 18:30 GMT

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean ...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP-1 dual agonist, from baseline.1 Detailed pre- …

Distribution channels:

Published on June 7, 2026 - 17:30 GMT

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for ...

AT7687 demonstrated a favorable safety and tolerability profile with no adverse GI tolerability signals identified Once-weekly dosing potential and demonstrated target engagement across the doses tested were confirmed Preclinical data from non-human …

Distribution channels: Technology ...

Published on June 7, 2026 - 16:46 GMT

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Veritone, Inc. Investors to Secure Counsel Before Important Deadline in Securities ...

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Veritone, Inc. (NASDAQ: VERI) between October 14, 2025 and April 14, 2026, inclusive (the “Class Period”), of the …

Distribution channels: